{"id":"fazaclo","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Tachycardia","drugRate":"25%","severity":"common"},{"effect":"Sedation","drugRate":"21%","severity":"common"},{"effect":"Constipation","drugRate":"16%","severity":"common"},{"effect":"Dizziness","drugRate":"14%","severity":"common"},{"effect":"Hypotension","drugRate":"13%","severity":"common"},{"effect":"Fever","drugRate":"12%","severity":"common"},{"effect":"Hypersalivation","drugRate":"11%","severity":"common"},{"effect":"Sweating","drugRate":"6%","severity":"mild"},{"effect":"Dry Mouth","drugRate":"6%","severity":"mild"},{"effect":"Visual Disturbances","drugRate":"5%","severity":"mild"},{"effect":"Nausea","drugRate":"5%","severity":"mild"},{"effect":"Salivary hypersecretion","drugRate":"48%","severity":"common"},{"effect":"Somnolence","drugRate":"46%","severity":"common"},{"effect":"Weight increased","drugRate":"31%","severity":"common"},{"effect":"Dizziness (excluding vertigo)","drugRate":"27%","severity":"common"},{"effect":"Insomnia","drugRate":"20%","severity":"common"},{"effect":"Nausea/Vomiting","drugRate":"17%","severity":"common"},{"effect":"Vomiting","drugRate":"17%","severity":"common"},{"effect":"Dyspepsia","drugRate":"14%","severity":"common"},{"effect":"Dystonia","drugRate":"reported","severity":"unknown"},{"effect":"Delirium","drugRate":"reported","severity":"unknown"},{"effect":"EEG abnormal","drugRate":"reported","severity":"unknown"},{"effect":"Myoclonus","drugRate":"reported","severity":"unknown"},{"effect":"Paresthesia","drugRate":"reported","severity":"unknown"},{"effect":"Possible cataplexy","drugRate":"reported","severity":"unknown"},{"effect":"Status epilepticus","drugRate":"reported","severity":"unknown"},{"effect":"Obsessive compulsive symptoms","drugRate":"reported","severity":"unknown"},{"effect":"Post-discontinuation cholinergic rebound adverse reactions","drugRate":"reported","severity":"unknown"}],"contraindications":["Agranulocytosis","Alcohol-induced psychosis","Angle-closure glaucoma","At risk for aspiration","Benign prostatic hyperplasia","Bone marrow depression","Breastfeeding (mother)","Central nervous system depression","Cerebrovascular accident","Cerebrovascular disease","Coma","Conduction disorder of the heart","Constipation","Decreased respiratory function","Deep venous thrombosis","Dehydration","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Drug-induced neutropenia","Eosinophil count raised","Fecal impaction","Gastrointestinal hypomotility","Hyperglycemia","Hyperlipidemia","Leukopenia","Liver function tests abnormal","Low blood pressure","Lowered convulsive threshold","Metabolic syndrome X","Myocarditis","Neoplastic Myeloproliferative Disorders","Neuroleptic malignant syndrome","Neutropenic disorder","Obesity","Orthostatic hypotension","Paralytic ileus","Primary dilated cardiomyopathy","Pulmonary thromboembolism","Retention of urine","Seizure disorder","Senile dementia","Sinus tachycardia","Substance Overdose","Syncope","Tardive dyskinesia","Uncontrolled Epilepsy"]},"trials":[],"_chembl":{"chemblId":"CHEMBL42","moleculeType":"Small molecule","molecularWeight":"326.83"},"aliases":["Fazaclo clozapine"],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:53:42.191238","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T00:39:38.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Suicidal Behavior in Schizoaffective Disorder","diseaseId":"suicidal-behavior-in-schizoaffective-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Suicidal Behavior in Schizophrenia","diseaseId":"suicidal-behavior-in-schizophrenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Treatment-Resistant Schizophrenia","diseaseId":"treatment-resistant-schizophrenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT06993662","phase":"PHASE1","title":"The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rakitzi, Stavroula","startDate":"2025-06-02","conditions":"Anxiety, Depression, Obsessive-compulsive Disorder","enrollment":107},{"nctId":"NCT04580134","phase":"PHASE4","title":"CLOZAPINE Response in Biotype-1","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-03-01","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder","enrollment":524},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT06456983","phase":"NA","title":"Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial","status":"RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2025-02-14","conditions":"Schizophrenia, Treatment Resistant Schizophrenia","enrollment":140},{"nctId":"NCT05208190","phase":"PHASE4","title":"Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-17","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":280},{"nctId":"NCT06596681","phase":"EARLY_PHASE1","title":"A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-09-11","conditions":"Pain, Intractable","enrollment":6},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT05316883","phase":"PHASE4","title":"Biomarkers in Clozapine-responding Schizophrenia","status":"RECRUITING","sponsor":"Jimmi Nielsen","startDate":"2021-02-28","conditions":"Schizophrenia, Psychosis","enrollment":200},{"nctId":"NCT06003036","phase":"NA","title":"Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine","status":"RECRUITING","sponsor":"Deepak K. Sarpal, M.D.","startDate":"2023-12-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":30},{"nctId":"NCT07326124","phase":"PHASE3","title":"Stratification and Treatment in Early Psychosis Study -ASSIST","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-06","conditions":"Treatment Resistant Psychosis, Psychosis","enrollment":250},{"nctId":"NCT07262736","phase":"PHASE1","title":"Pharmacokinetics of Clozapine and Norclozapine and the Effect of Pantoprazole","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2021-02-06","conditions":"Healthy Volunteers - Male and Female","enrollment":33},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":"Psychotic Disorders","enrollment":50},{"nctId":"NCT06634641","phase":"PHASE4","title":"Clozapine-related Immunodeficiency in Parkinsons Disease","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2024-10-01","conditions":"Clozapine, Parkinson's Disease (PD), Immunodeficiency","enrollment":24},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT05958875","phase":"PHASE4","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2024-08-01","conditions":"Schizophrenia and Related Disorders, Early Treatment-Resistance","enrollment":418},{"nctId":"NCT04325386","phase":"NA","title":"Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2020-02-01","conditions":"Schizophrenia Schizoaffective","enrollment":266},{"nctId":"NCT07085195","phase":"EARLY_PHASE1","title":"A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-01","conditions":"Parkinson Disease (PD), Gene Therapy, Safety and Efficacy","enrollment":6},{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT06174116","phase":"PHASE4","title":"Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia","status":"RECRUITING","sponsor":"University of Massachusetts, Worcester","startDate":"2024-04-02","conditions":"Schizophrenia, Schizo Affective Disorder","enrollment":50},{"nctId":"NCT06754163","phase":"PHASE4","title":"Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients","status":"RECRUITING","sponsor":"St Andrew's Healthcare","startDate":"2025-01-01","conditions":"Obesity and Obesity-related Medical Conditions, Psychiatric Disorders","enrollment":20},{"nctId":"NCT06969755","phase":"PHASE4","title":"Biomarkers to Enhance Early Schizophrenia Treatment","status":"NOT_YET_RECRUITING","sponsor":"Northwell Health","startDate":"2025-07-30","conditions":"Schizophenia Disorder","enrollment":180},{"nctId":"NCT05944510","phase":"PHASE4","title":"Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-08-31","conditions":"Treatment Resistant Schizophrenia","enrollment":40},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT06906224","phase":"EARLY_PHASE1","title":"Effects of Buspirone Combined With Clozapine","status":"COMPLETED","sponsor":"Chuanfu Song","startDate":"2022-05-01","conditions":"Schizophrenia","enrollment":46},{"nctId":"NCT00178932","phase":"NA","title":"Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors","status":"COMPLETED","sponsor":"Northwestern University","startDate":"1998-11","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":37},{"nctId":"NCT03076346","phase":"","title":"Neural Biomarkers of Clozapine Response","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2017-09-01","conditions":"Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder","enrollment":41},{"nctId":"NCT06749041","phase":"","title":"Nor)Clozapine Kinetics and Side Effects in Therapy Resistant Schizophrenia and the Optimal Sampling Time for Therapeutic Drug Monitoring","status":"NOT_YET_RECRUITING","sponsor":"GGZ Noord-Holland-Noord","startDate":"2024-12-23","conditions":"Cardiovascular Side Effects of Clozapine, Neutropenia Due to Clozapine, General Side Effects of Clozapine","enrollment":60},{"nctId":"NCT03263533","phase":"EARLY_PHASE1","title":"HDAC Inhibitor Augmentation to Clozapine","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2017-04","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT04892199","phase":"PHASE4","title":"Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2021-09-01","conditions":"Metabolic Disturbance, Schizophrenia, Type 2 Diabetes","enrollment":104},{"nctId":"NCT06610500","phase":"","title":"Clozapine Hematological Monitoring Regulatory Compliance Assessment in Psychiatry","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-05-16","conditions":"Schizophrenia, Agranulocytosis","enrollment":20},{"nctId":"NCT06573320","phase":"NA","title":"Effect of Exercise on Clinical Symptoms, Cognitive Performance, and Quality of Life in Schizophrenia Patients Treated With Clozapine","status":"RECRUITING","sponsor":"Dr. Lutfi Kirdar Kartal Training and Research Hospital","startDate":"2024-03-14","conditions":"Schizophrenia, Clozapine, Exercise","enrollment":60},{"nctId":"NCT02640300","phase":"PHASE4","title":"Switching Antipsychotics: Abrupt Discontinuation Versus Overlap","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"1999-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":33},{"nctId":"NCT06505668","phase":"NA","title":"Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-08-01","conditions":"Treatment Resistant Schizophrenia, Clozapine Adverse Reaction, Heart Rate Variability","enrollment":40},{"nctId":"NCT06501339","phase":"PHASE4","title":"Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-08-10","conditions":"Clozapine Resistant Schizophrenia","enrollment":40},{"nctId":"NCT06413589","phase":"PHASE2","title":"Efficacy of SMOF Lipid in the Management of Acute Poisoning With Clozapine","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-01-01","conditions":"Acute Poisoning","enrollment":40},{"nctId":"NCT04529226","phase":"PHASE2","title":"Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-11-26","conditions":"Psychosis, Intellectual Disability","enrollment":75},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06159322","phase":"","title":"Characterizing Response to Antipsychotics in Schizophrenia","status":"UNKNOWN","sponsor":"The Royal Ottawa Mental Health Centre","startDate":"2023-01-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":40},{"nctId":"NCT02140788","phase":"PHASE4","title":"Effects of Metformin and Fish Oil on Treatment With Clozapine","status":"TERMINATED","sponsor":"Duke University","startDate":"2011-05","conditions":"Schizophrenia, Schizo-affective Disorder","enrollment":34},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT02639702","phase":"PHASE4","title":"Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2016-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":30},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT06011460","phase":"","title":"Observation of Clozapine Treatment Safety in Bipolar Disorder.","status":"ENROLLING_BY_INVITATION","sponsor":"Medical University of Gdansk","startDate":"2023-02-23","conditions":"Bipolar Disorder","enrollment":30},{"nctId":"NCT05766540","phase":"PHASE4","title":"Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-08-20","conditions":"Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia","enrollment":60},{"nctId":"NCT05919550","phase":"","title":"Clozapine-associated Infection","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2023-04-11","conditions":"Infections","enrollment":26815616},{"nctId":"NCT05422131","phase":"","title":"Clozapine Therapy Sample Collection - Method Comparison Study","status":"COMPLETED","sponsor":"Saladax Biomedical, Inc.","startDate":"2022-11-12","conditions":"Patients Prescribed Clozapine","enrollment":153},{"nctId":"NCT04849026","phase":"PHASE1","title":"Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18","status":"COMPLETED","sponsor":"Whanin Pharmaceutical Company","startDate":"2021-01-15","conditions":"Schizophrenia","enrollment":33},{"nctId":"NCT02404155","phase":"NA","title":"Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2015-07","conditions":"Schizophrenia","enrollment":274},{"nctId":"NCT05632094","phase":"PHASE2","title":"The Efficacy of L-Carnitine in the Management of Acute Clozapine Intoxication","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2023-06","conditions":"Clozapine Poisoning","enrollment":40},{"nctId":"NCT04197037","phase":"","title":"Prevalence of Sialorrhea in Patients Treated With Clozapine","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2018-03-20","conditions":"Sialorrhea, Clozapine Adverse Reaction, Quality of Life","enrollment":129},{"nctId":"NCT03652974","phase":"PHASE4","title":"Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2018-09-06","conditions":"Schizophrenia","enrollment":145},{"nctId":"NCT02714894","phase":"","title":"Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2016-04","conditions":"Schizophrenia","enrollment":108},{"nctId":"NCT02533232","phase":"PHASE1","title":"Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia","status":"UNKNOWN","sponsor":"Pakistan Institute of Living and Learning","startDate":"2022-08-30","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":60},{"nctId":"NCT03852706","phase":"NA","title":"EEG-based Neurofeedback for Auditory Verbal Hallucinations (HALFEED)","status":"TERMINATED","sponsor":"University of Dublin, Trinity College","startDate":"2019-03-01","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT00176436","phase":"PHASE4","title":"Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2004-02","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT03772951","phase":"PHASE4","title":"The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-01-10","conditions":"Schizophrenia","enrollment":154},{"nctId":"NCT05083377","phase":"","title":"Clozapine Use Pattern in the Province of Seville","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-09-08","conditions":"Schizophrenia and Related Disorders","enrollment":600},{"nctId":"NCT02286206","phase":"PHASE4","title":"Study of the Effect of Dosing on Clozapine Levels","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2015-01","conditions":"Psychotic Disorders, Schizophrenia","enrollment":""},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03094429","phase":"PHASE2, PHASE3","title":"An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults","status":"RECRUITING","sponsor":"SyneuRx International (Taiwan) Corp","startDate":"2017-03-29","conditions":"Refractory Schizophrenia","enrollment":287},{"nctId":"NCT02439099","phase":"","title":"Retinoic Acid Homeostasis in Neuropsychiatric Diseases","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2015-03","conditions":"Major Depression, Alzheimer's Disease, Alcoholism","enrollment":200},{"nctId":"NCT03807882","phase":"PHASE4","title":"Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2019-02-01","conditions":"Treatment Resistant Schizophrenia","enrollment":60},{"nctId":"NCT04898270","phase":"PHASE4","title":"Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2019-12-19","conditions":"Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol","enrollment":30},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00649844","phase":"PHASE3","title":"A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-01","conditions":"Schizophrenia","enrollment":147},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT00154258","phase":"PHASE2","title":"A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"Novartis","startDate":"2001-04","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT04528095","phase":"PHASE3","title":"SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-12","conditions":"Treatment-resistant Schizophrenia","enrollment":162},{"nctId":"NCT01639872","phase":"PHASE4","title":"Clozapine for Cannabis Use in Schizophrenia","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2013-05-01","conditions":"Schizophrenia, Cannabis Abuse, Cannabis Dependence","enrollment":49},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03857581","phase":"PHASE4","title":"Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder","status":"UNKNOWN","sponsor":"Augusta University","startDate":"2020-07","conditions":"Psychosis, Substance Use Disorders","enrollment":100},{"nctId":"NCT03253367","phase":"","title":"Phenomics and Genomics of Clozapine Pharmacotherapy","status":"UNKNOWN","sponsor":"Jurjen Luykx","startDate":"2016-01-19","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":2500},{"nctId":"NCT04240496","phase":"NA","title":"Clinical and Genetic Influencing Factors on Clozapine Pharmacokinetics","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2019-10-17","conditions":"CYP1A2 Polymorphism, CYP2C19 Polymorphism, Clozapine","enrollment":51},{"nctId":"NCT00056498","phase":"PHASE4","title":"Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2001-12","conditions":"Schizophrenia","enrollment":65},{"nctId":"NCT03523741","phase":"","title":"Therapeutic Drug Monitoring for Individualized Clozapine Therapy","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-06-13","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT04074213","phase":"","title":"Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-03-01","conditions":"Lymphoma, Leukemia","enrollment":1000000},{"nctId":"NCT01433055","phase":"NA","title":"Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-07","conditions":"Schizophrenia","enrollment":52},{"nctId":"NCT00573287","phase":"NA","title":"First Episode Schizophrenia and Cannabis-Related Disorder Study","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2006-06","conditions":"Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia","enrollment":14},{"nctId":"NCT03996122","phase":"","title":"Research of Anatomo-functional Biomarkers in Schizophrenia","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-04-04","conditions":"Schizophrenia","enrollment":15},{"nctId":"NCT03996356","phase":"","title":"Clozapine Induced Weight Gain","status":"UNKNOWN","sponsor":"Cwm Taf University Health Board (NHS)","startDate":"2020-03","conditions":"Weight Gain, Antipsychotic Agents, Pharmacogenetics","enrollment":160},{"nctId":"NCT01567124","phase":"PHASE4","title":"Alleviating the Metabolic Side Effects of Antipsychotic Medications","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT02248987","phase":"","title":"Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-05","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT00498550","phase":"PHASE4","title":"Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2000-10","conditions":"Schizophrenia, Dual Diagnosis, Schizoaffective Disorder","enrollment":31},{"nctId":"NCT02926976","phase":"NA","title":"The Optimal Treatment for Treatment-resistant Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2016-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":"Obesity, Weight Gain, Psychotropic Induced Weight Gain","enrollment":96},{"nctId":"NCT00690235","phase":"PHASE4","title":"Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-11","conditions":"Schizophrenia, Schizoaffective Disorder, Diabetes","enrollment":33},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT02562287","phase":"PHASE4","title":"Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2015-10","conditions":"Bipolar Disorder","enrollment":54},{"nctId":"NCT02124811","phase":"PHASE4","title":"Minocycline Augmentation to Clozapine","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-02","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":10},{"nctId":"NCT01654640","phase":"PHASE4","title":"The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2012-09","conditions":"Schizophrenia","enrollment":15},{"nctId":"NCT03651674","phase":"NA","title":"Longitudinal Effect of Electroconvulsive Therapy on Schizophrenia and Bipolar Disorder: a MRI Study","status":"UNKNOWN","sponsor":"Xidian University","startDate":"2018-09-20","conditions":"Schizophrenia, Bipolar Disorder","enrollment":200},{"nctId":"NCT02529163","phase":"NA","title":"Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2015-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":24},{"nctId":"NCT00981526","phase":"PHASE4","title":"Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":66},{"nctId":"NCT01248195","phase":"PHASE4","title":"Optimization of Treatment and Management of Schizophrenia in Europe","status":"COMPLETED","sponsor":"Rene Kahn","startDate":"2011-05","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":479},{"nctId":"NCT01280396","phase":"","title":"Metabolic Side-effects for Second-generation Antipsychotics","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2010-11","conditions":"Mental Disorders","enrollment":241},{"nctId":"NCT00169026","phase":"PHASE4","title":"Alcoholism and Schizophrenia: Effects of Clozapine","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"1999-05","conditions":"Schizophrenia, Dual Diagnosis, Schizoaffective Disorder","enrollment":64},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407}],"_emaApprovals":[],"_faersSignals":[{"count":119,"reaction":"DEATH"},{"count":47,"reaction":"AGRANULOCYTOSIS"},{"count":45,"reaction":"PNEUMONIA"},{"count":37,"reaction":"HOSPITALISATION"},{"count":29,"reaction":"CARDIAC ARREST"},{"count":29,"reaction":"MYOCARDIAL INFARCTION"},{"count":20,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":20,"reaction":"NEUTROPENIA"},{"count":19,"reaction":"COMPLETED SUICIDE"},{"count":19,"reaction":"CONVULSION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Fazaclo","genericName":"Fazaclo","companyName":"Manhattan Psychiatric Center","companyId":"manhattan-psychiatric-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}